Introduction
India's emergence as a global clinical research destination is backed by substance. With over 1.4 billion people spanning diverse genetic backgrounds and disease profiles, a network of NABH-accredited hospitals, a growing base of GCP-trained investigators, and a regulatory framework that has been substantially modernized over the past decade, India now offers sponsors a genuinely competitive environment for conducting high-quality clinical trials.
What is a Clinical Trial?
A clinical trial is a prospective, structured research study conducted in human participants to evaluate the safety, efficacy, pharmacokinetics, or performance of a medical intervention — whether a new drug, biologic, medical device, or diagnostic tool. Trials are conducted across multiple phases, each answering progressively broader scientific questions, and every step must comply with ethical, scientific, and regulatory standards defined by national authorities and international guidelines.
In India, the governing regulatory instrument is the New Drugs and Clinical Trials (NDCT) Rules, 2019, which operates under the Drugs and Cosmetics Act, 1940. These rules define the legal framework within which every clinical trial on Indian soil must be conducted.
The 10-Step Clinical Trial Process in India
Step 1: Study Design and Protocol Development
Every clinical trial is built on its protocol — a detailed, legally binding document that defines the scientific rationale, objectives, study design, eligibility criteria, intervention plan, endpoints, statistical methodology, safety monitoring approach, and data collection procedures.
A poorly designed protocol is the single largest avoidable source of trial failure. Common protocol weaknesses include overly restrictive eligibility criteria that make enrollment unachievable, endpoints that cannot be reliably measured in the intended population, and visit schedules that create unacceptable patient burden.
Best-practice protocol development involves early input from biostatisticians (to ensure the study is adequately powered), regulatory affairs specialists (to align with CDSCO and ICH expectations), clinical investigators (to assess operational feasibility), and ideally patient representatives (to evaluate acceptability from the participant's perspective).
For trials being conducted simultaneously in multiple countries, the India-specific protocol must account for local standard of care, available concomitant medications, and any population-specific considerations that may affect dosing, endpoints, or safety monitoring.
Step 2: Regulatory Approval (CDSCO)
All clinical trials involving new drugs, investigational new drugs, or new medical devices in India require prior approval from the Central Drugs Standard Control Organisation (CDSCO), India's national regulatory authority for pharmaceuticals and medical devices.
The submission package — filed through the Sugam online portal — typically includes:
- The complete clinical trial protocol and any amendments
- Investigator's Brochure (IB) or equivalent device documentation
- Pre-clinical and prior clinical data supporting the proposed study
- Proposed informed consent documents
- Investigator CVs and site credentials
- Chemistry, Manufacturing and Controls (CMC) data for investigational products
- Risk-benefit assessment and justification
Under the NDCT Rules, 2019, CDSCO targets a 30-day review timeline for trials of drugs already approved in ICH countries (where India may conduct simultaneous global trials) and longer timelines for first-in-human or entirely novel interventions. In practice, sponsors should engage in pre-submission scientific advice meetings with CDSCO whenever possible — these interactions improve submission quality and reduce the risk of major deficiency letters.
Step 3: Ethics Committee Registration and Approval
Parallel to regulatory submission, sponsors must obtain approval from a registered Ethics Committee (EC) — also referred to internationally as an Institutional Review Board (IRB).
Under the NDCT Rules, 2019, Ethics Committees must be registered with CDSCO to review clinical trials. This registration requirement was introduced to ensure that ECs meet minimum standards for composition, operational procedures, and member training.
The EC evaluates:
- Scientific validity and relevance of the research
- Risk-benefit profile for participants
- Adequacy and clarity of informed consent documents
- Appropriateness of compensation provisions for trial-related injuries
- Measures to protect vulnerable populations
Compensation for trial-related injury or death is a mandatory requirement under Indian regulations — one of the more progressive provisions in the NDCT Rules, 2019. The compensation formula considers the nature of the injury, participant's income, and degree of relatedness to the trial intervention.
In multi-site trials, each site requires EC approval from its own registered committee. Sponsors and CROs must build EC review timelines — which can range from 4 to 12 weeks depending on the committee — into their overall study activation plans.
Step 4: Site Selection and Investigator Initiation
Site selection is one of the highest-leverage decisions in the entire trial process. Research consistently shows that a minority of sites — often 20% — contribute the majority of enrolled patients. Selecting the right sites from the outset materially determines whether a trial meets its enrollment targets and timeline.
A rigorous site feasibility assessment evaluates:
- Patient database size and accessibility: Does the site actually have patients who meet eligibility criteria in sufficient numbers?
- Investigator experience: Has the Principal Investigator conducted GCP-compliant trials previously? In which therapeutic areas?
- Staff capacity: Are dedicated clinical research coordinators available, or will research responsibilities compete with routine clinical workload?
- Infrastructure: Does the site have adequate pharmacy storage, laboratory capabilities, and emergency facilities required by the protocol?
- Competing trial burden: Is the site simultaneously running other studies targeting the same patient population?
Following site selection, site initiation visits (SIVs) ensure that all staff are trained on the protocol, investigational product handling, data entry procedures, and regulatory requirements before the first patient is screened.
👉 Learn more about our Clinical Operations
Step 5: Investigational Product Import and Supply Management
For international trials, investigational products must be imported into India under a CDSCO import license. This is a regulatory step that is frequently underestimated in study timelines — import clearance can take 4 to 8 weeks and requires coordination between the sponsor, CRO, customs broker, and site pharmacy.
Investigational product (IP) management in India must comply with GCP requirements for receipt, storage, dispensing, accountability, and return or destruction. Cold-chain products — biologics, vaccines, certain oncology agents — require validated storage systems and documented temperature monitoring throughout the supply chain.
Step 6: Patient Recruitment and Enrollment
Patient recruitment is persistently cited as the most operationally challenging phase of clinical trial conduct. Approximately 80% of trials fail to meet their original enrollment timelines, and delayed enrollment is the most common driver of trial cost overruns.
Effective recruitment in India requires:
- Site-level patient identification strategies tailored to the therapeutic area and site's patient flow
- Community engagement and physician referral networks for trials requiring patients outside the site's immediate catchment area
- Clear, culturally appropriate participant-facing materials in regional languages — not just English translations of Western documents
- Screening-to-enrollment ratio analysis to identify and address protocol design barriers to eligibility
Retention is equally important. Once enrolled, participants must remain engaged and compliant throughout the study duration. This requires proactive communication, responsive handling of participant concerns, flexible visit scheduling where protocol permits, and — increasingly — decentralized trial elements such as home visits and remote assessments.
👉 Learn more about Patient Recruitment Challenges in Clinical Trials
Step 7: Trial Conduct and GCP-Compliant Monitoring
Once the trial is active, it must be conducted in strict accordance with the approved protocol, ICH E6(R2) GCP guidelines, and CDSCO requirements. This is the responsibility of both the investigator site and the sponsor (or its appointed CRO).
Monitoring — the primary mechanism through which sponsors verify trial conduct quality — has evolved significantly. Under Risk-Based Monitoring (RBM) frameworks now expected by CDSCO and international regulators:
- Centralized statistical monitoring identifies data anomalies across sites that on-site visits alone would miss
- Remote monitoring of electronic source data reduces travel costs and enables more frequent oversight of critical data points
- Targeted on-site visits address specific risk signals rather than following fixed, uniform schedules
Protocol deviations — departures from the approved protocol — must be documented, assessed for their impact on participant safety and data integrity, and reported to the EC and CDSCO as required by severity and nature.
👉 Explore Clinical Data Management in Clinical Trials
Step 8: Data Collection, Management, and Integrity
All clinical trial data in India must meet ALCOA+ standards — data must be Attributable, Legible, Contemporaneous, Original, and Accurate, as well as Complete, Consistent, Enduring, and Available.
Electronic Data Capture (EDC) systems used in Indian trials must comply with 21 CFR Part 11 requirements for electronic records and signatures, and must be validated before use. Data validation checks, query management, and audit trail reviews should occur in real time — not at database lock.
The Clinical Trials Registry – India (CTRI), maintained by the Indian Council of Medical Research (ICMR), requires prospective registration of all clinical trials before enrollment of the first participant. Registration is a regulatory and ethical obligation — and CTRI registration details must be consistent with the approved protocol.
👉 Explore What is Pharmacovigilance and Why It Matters in Clinical Trials
Step 9: Safety Monitoring and Pharmacovigilance
Participant safety monitoring is a continuous obligation throughout the trial lifecycle. In India, the NDCT Rules, 2019 specify detailed requirements for Serious Adverse Event (SAE) reporting, including:
- Suspected Unexpected Serious Adverse Reactions (SUSARs): Must be reported to CDSCO within 15 calendar days (7 days for fatal or life-threatening cases)
- Annual Safety Reports: Submitted to CDSCO and the EC summarizing the cumulative safety profile of the investigational product
- Data Safety Monitoring Board (DSMB): Required for trials involving significant risk — the DSMB conducts independent interim safety reviews and can recommend trial modification or termination
Investigator sites must report SAEs to the sponsor within 24 hours of awareness, with follow-up narratives submitted as information becomes available. Systematic tracking of adverse event reporting timelines is a frequent focus of regulatory inspections.
👉 Explore our Statistical Analysis
Step 10: Data Analysis, Clinical Study Report, and Regulatory Submission
Following database lock, statistical analysis is conducted according to the pre-specified Statistical Analysis Plan (SAP) — a document that must be finalized and locked before unblinding to prevent post-hoc analytical decisions that could bias conclusions.
The Clinical Study Report (CSR) — structured per ICH E3 guidelines — is the primary document submitted to regulatory authorities as evidence of trial outcomes. For new drug applications in India, this is submitted to CDSCO as part of the New Drug Application (NDA) or Marketing Authorization Application (MAA).
CDSCO review timelines for marketing applications vary by application type and regulatory pathway. For drugs already approved in major ICH markets (US, EU, Japan, Australia, Canada), India now allows accelerated review under provisions introduced by the NDCT Rules — a significant improvement over the historical practice of requiring Indian trials to be completed after global approvals.
Key Regulatory Guidelines in India
Why Conduct Clinical Trials in India?
Beyond regulatory modernization, India's structural advantages for clinical research are well-established:
Patient Access: A large population with high disease burden across therapeutic areas — including infectious diseases, oncology, cardiovascular, diabetes, and rare diseases — provides access to patient populations that are difficult to recruit efficiently in saturated Western markets.
Cost Efficiency: Per-patient trial costs in India are estimated at 40–60% lower than equivalent studies in the US or Western Europe, driven by lower site operational costs, investigator fees, and laboratory costs — without compromising GCP compliance.
Scientific Workforce: India produces a substantial annual output of physicians, pharmacists, biostatisticians, and clinical research professionals trained to international standards.
Genetic Diversity: Inclusion of Indian patients in global trials strengthens the generalizability of safety and efficacy data across diverse populations — an increasingly explicit expectation in FDA and EMA guidance on diversity in clinical trials.
The Role of a CRO in the Indian Clinical Trial Process
For most sponsors — particularly those without an established operational presence in India — a Contract Research Organization (CRO) provides the local expertise, site relationships, regulatory knowledge, and operational infrastructure necessary to execute trials efficiently and compliantly.
An experienced India-based CRO contributes:
- Regulatory navigation: CDSCO submission strategy, EC liaison, and ongoing regulatory compliance management
- Site network: Established relationships with qualified investigator sites across therapeutic areas and geographies
- Operational execution: Patient recruitment, monitoring, data management, and safety reporting
- Local knowledge: Understanding of regional patient populations, language requirements, cultural considerations, and operational realities
👉 Read more: What is a CRO and its Role in Clinical Research
Conclusion
The clinical trial process in India is rigorous, multi-stakeholder, and increasingly aligned with global standards. Each step — from protocol design through regulatory submission — carries specific requirements that must be met for a trial to be scientifically valid, ethically sound, and regulatorily acceptable.
For sponsors considering India as a trial destination, the combination of regulatory modernization, patient diversity, cost competitiveness, and an experienced CRO ecosystem makes a compelling case. Success, however, depends on understanding the process in depth — and partnering with organizations that have navigated it repeatedly.
Genelife Clinical Research Pvt. Ltd. is a full-service CRO with deep expertise in India's regulatory environment and clinical trial operations. Visit www.genelifecr.com to learn how we support sponsors through every step of the clinical trial process.
Related Insights
Genelife Perspective of Best Practices in Study Management
No comments:
Post a Comment